Resources Repository
-
GuidelinesPublication 2016Second Panel on Cost-Effectiveness in Health and Medicine
This article provides an overview of the main recommendations of the 2016 Second Panel on …
This article provides an overview of the main recommendations of the 2016 Second Panel on Cost-Effectiveness in Health and Medicine. In 1993, the U.S. Public Health Service convened the first panel of experts to review the state of cost-effectiveness analysis and to develop guidelines for its use in health, to improve quality and promote comparability. Scientists and scholars in economics, clinical medicine, ethics, and statistics met to share expertise and develop recommendations by consensus. The…
Evidence Synthesis | Priority Setting/Ethics | Cost-Effectiveness Analysis | Costing Methods | North America | Technology Assessment | Health/Medicine -
ReportPublication 2018Estimating the Distributional Impact of Increasing Taxes on Tobacco Products in Armenia
Smoking is considered the leading risk factor for mortality among the Armenian population. The authors …
Smoking is considered the leading risk factor for mortality among the Armenian population. The authors conducted an extended cost-effectiveness analysis (ECEA) on increases in the excise tax on cigarettes in Armenia. Based on the World Health Organization recommendations, they analyzed the impact of a 75% increase of excise tax on the retail price of cigarettes. The ECEA found large health and financial benefits to the excise tax. It averted about 88,000 premature deaths, US$63 million of OOP…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Europe | Chronic Disease/Risk | Health Systems | Policy/Regulation | Business/Industry | Economics/Finance | Government/Law | Health/Medicine -
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Cost-Effectiveness Analysis | Europe | North America | Preferences/Values | Health Outcomes | Mathematical Models | Technology Assessment | Health Systems | Health/Medicine | Science/Technology -
GuidelinesPublication 2016Methods for Health Economic Evaluation of Vaccines
This article describes the development of a consensus for health economic evaluations of vaccines to …
This article describes the development of a consensus for health economic evaluations of vaccines to support the development of national guidelines in Europe. While guidelines advocating more standardization of health economic evaluations exist, this article aims to address several immunization-specific aspects (e.g. indirect effects or discounting approach) which are still a subject of debate. The systematic literature review search was informed by expert opinion. 2,838 articles were returned from the search and 26 were finally…
Cost-Effectiveness Analysis | Costing Methods | Europe | Dynamic Transmission | Infectious Diseases | Health Systems | Health/Medicine -
GuidelinesPublication 2015USPSTF Procedure Manual
The U.S. Preventive Services Task Force (USPSTF) Procedure Manual describes the methods used by the …
The U.S. Preventive Services Task Force (USPSTF) Procedure Manual describes the methods used by the Task Force to ensure that its recommendations are scientifically sound, reproducible, and well documented. The Manual provides a high-level description of the Task Force’s structure, governance, and processes for selecting topics, reviewing evidence, soliciting and responding to public input, and arriving at a recommendation. It is intended as a guide for anyone who is interested in the Task Force, Task…
Evidence Synthesis | Priority Setting/Ethics | North America | Technology Assessment | Health Systems | Policy/Regulation | Government/Law | Health/Medicine -
ReportPublication 2015Returns on HTA Funded Research
This report from the RAND Corporation dissects the impact of the Health Technology Assessment (HTA) …
This report from the RAND Corporation dissects the impact of the Health Technology Assessment (HTA) program in making quality research accessible and cost-effective. The authors conduct an economic analysis to illustrate benefits of new interventions in two ways: through improved health, measured in QALYs, and through showing that the intervention allows for the same health outcome and a lower cost. The report utilizes economic analyses and case studies to make recommendations. These recommendations include considering…
Evidence Synthesis | Costing Methods | Europe | Health Outcomes | Health Systems | Economics/Finance | Health/Medicine | Science/Technology -
ReportPublication 2015Opioid Dependence: Final Report
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value …
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value of interventions for the management of opioid dependence. The goals of the report are to document the federal and New England state regulations affecting treatment options, provide an overview of existing clinical guidelines and payer coverage policies, and summarize the evidence on the different management approaches for opioid dependence, including special considerations for adolescents. An appendix is provided by ICER.…
Evidence Synthesis | Cost-Effectiveness Analysis | North America | Preferences/Values | Health Outcomes | Technology Assessment | Chronic Disease/Risk | Mental Health | Health Systems | Policy/Regulation | Business/Industry | Government/Law | Health/Medicine | Science/Technology -
ReportPublication 2014Redirecting Innovation in U.S. Health Care
This report from RAND Health explores methods of reducing health care spending and developing medical …
This report from RAND Health explores methods of reducing health care spending and developing medical products that provide cost value with health benefits. It summarizes literature and explores case studies to provide policy recommendations to meet these goals. It identifies a wide range of factors that affect the costs, risks, and rewards of medical product invention. Some of these features include treatment creep, the medical arms race, costs and risks of FDA approval, limited reward…
Evidence Synthesis | Costing Methods | North America | Health Outcomes | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine | Science/Technology -
GuidelinesPublication 2013Guide to the Methods of Technology Appraisal 2013
The National Institute for Health and Care Excellence (NICE, or the Institute) provides guidance to …
The National Institute for Health and Care Excellence (NICE, or the Institute) provides guidance to the NHS in England on the clinical and cost effectiveness of selected new and established technologies. The Institute undertakes appraisals of health technologies at the request of the Department of Health. Guidance produced by the Institute on health technologies is also applied selectively in Northern Ireland, Scotland and Wales. The purpose of this document is to provide an overview of…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Europe | Technology Assessment | Health Systems | Policy/Regulation | Government/Law | Health/Medicine